Iron Overload in Patients Undergoing Donor Stem Cell Transplant
Status: | Completed |
---|---|
Conditions: | Cancer, Cancer, Blood Cancer, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 12/3/2017 |
Start Date: | December 2008 |
End Date: | June 2012 |
Iron Overload in Allogeneic Hematopoietic Cell Transplantation
RATIONALE: Learning about the effect of excess iron in the liver of patients undergoing donor
stem cell transplant may help doctors plan treatment.
PURPOSE: This study is investigating the effects of iron overload in patients undergoing
donor stem cell transplant.
stem cell transplant may help doctors plan treatment.
PURPOSE: This study is investigating the effects of iron overload in patients undergoing
donor stem cell transplant.
OBJECTIVES:
Primary
- Determine the impact of pre-transplant iron overload (defined as liver iron
concentration [LIC] above normal [> 1.8 mg/g] on an MRI of the liver measuring tissue
proton transverse relaxation rates [R2 MRI]) on the probability of 1-year overall
survival of patients undergoing allogeneic hematopoietic stem cell transplantation
(HSCT).
Secondary
- Determine the impact of pre-transplant iron overload on the composite endpoint of
non-relapse mortality and complications (e.g., serious infections, hepatic
veno-occlusive disease, or organ failure) within 1 year after allogeneic HSCT.
- Determine the impact of pre-transplant iron overload on the 1-year cumulative incidence
of acute or chronic graft-vs-host disease in patients with acute leukemia or
myelodysplastic syndromes undergoing allogeneic HSCT.
- Determine the impact of pre-transplant iron overload on the 1-year probability of
overall survival and non-relapse mortality in patients undergoing allogeneic HSCT.
- Determine the prevalence of pre-transplant iron overload in adult patients undergoing
allogeneic HSCT.
- Determine the correlation between pre-transplant ferritin levels and LIC on R2 MRI.
- Compare the longitudinal measures of serum ferritin levels after allogeneic HSCT in
patients with iron overload vs those without iron overload.
- Estimate the cumulative incidence of iron overload at 1 year after allogeneic HSCT.
OUTLINE: Patients undergo blood sample collection to measure serum ferritin levels at
baseline (pre-transplant) and then at 3, 6, 9, and 12 months after transplant. Patients with
serum ferritin > 500 ng/mL also undergo an R2 MRI at baseline (pre-transplant) and at 12
months after transplant to determine liver iron concentration. Patients with serum ferritin >
500 ng/mL at 12 months after transplant also undergo an R2 MRI.
Primary
- Determine the impact of pre-transplant iron overload (defined as liver iron
concentration [LIC] above normal [> 1.8 mg/g] on an MRI of the liver measuring tissue
proton transverse relaxation rates [R2 MRI]) on the probability of 1-year overall
survival of patients undergoing allogeneic hematopoietic stem cell transplantation
(HSCT).
Secondary
- Determine the impact of pre-transplant iron overload on the composite endpoint of
non-relapse mortality and complications (e.g., serious infections, hepatic
veno-occlusive disease, or organ failure) within 1 year after allogeneic HSCT.
- Determine the impact of pre-transplant iron overload on the 1-year cumulative incidence
of acute or chronic graft-vs-host disease in patients with acute leukemia or
myelodysplastic syndromes undergoing allogeneic HSCT.
- Determine the impact of pre-transplant iron overload on the 1-year probability of
overall survival and non-relapse mortality in patients undergoing allogeneic HSCT.
- Determine the prevalence of pre-transplant iron overload in adult patients undergoing
allogeneic HSCT.
- Determine the correlation between pre-transplant ferritin levels and LIC on R2 MRI.
- Compare the longitudinal measures of serum ferritin levels after allogeneic HSCT in
patients with iron overload vs those without iron overload.
- Estimate the cumulative incidence of iron overload at 1 year after allogeneic HSCT.
OUTLINE: Patients undergo blood sample collection to measure serum ferritin levels at
baseline (pre-transplant) and then at 3, 6, 9, and 12 months after transplant. Patients with
serum ferritin > 500 ng/mL also undergo an R2 MRI at baseline (pre-transplant) and at 12
months after transplant to determine liver iron concentration. Patients with serum ferritin >
500 ng/mL at 12 months after transplant also undergo an R2 MRI.
Inclusion Criteria:
- Planning to undergo allogeneic hematopoietic stem cell transplantation using either
myeloablative or reduced-intensity conditioning
- Any diagnosis allowed
- Not pregnant
- Weight ≤ 350 lbs
- Must be able to give written informed consent indicating the investigational nature of
the study and its potential risks.
Exclusion Criteria:
- Claustrophobia
- Other contraindication for MRI (e.g., cardiac pacemaker, implanted cardiac
defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator, insulin
or infusion pump, or implanted drug infusion device)
We found this trial at
1
site
Click here to add this to my saved trials